Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,827 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer.
Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. Sinn BV, et al. Among authors: hoffmann g. Ann Oncol. 2013 Sep;24(9):2316-24. doi: 10.1093/annonc/mdt162. Epub 2013 May 9. Ann Oncol. 2013. PMID: 23661292 Free article. Clinical Trial.
Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765).
Noske A, Loibl S, Darb-Esfahani S, Roller M, Kronenwett R, Müller BM, Steffen J, von Toerne C, Wirtz R, Baumann I, Hoffmann G, Heinrich G, Grasshoff ST, Ulmer HU, Denkert C, von Minckwitz G. Noske A, et al. Among authors: hoffmann g. Breast Cancer Res Treat. 2011 Feb;126(1):109-17. doi: 10.1007/s10549-010-1316-y. Epub 2010 Dec 29. Breast Cancer Res Treat. 2011. PMID: 21190079 Clinical Trial.
Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B; GBG/AGO-B study groups; Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat… See abstract for full author list ➔ von Minckwitz G, et al. Among authors: hoffmann g. Ann Oncol. 2014 Dec;25(12):2363-2372. doi: 10.1093/annonc/mdu455. Epub 2014 Sep 15. Ann Oncol. 2014. PMID: 25223482 Free article. Clinical Trial.
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
van Rossum AGJ, Schouten PC, Weber KE, Nekljudova V, Denkert C, Solbach C, Köhne CH, Thomssen C, Forstbauer H, Hoffmann G, Kohls A, Schmatloch S, Schem C, von Minckwitz G, Karn T, Möbus VJ, Linn SC, Loibl S, Marmé F. van Rossum AGJ, et al. Among authors: hoffmann g. Breast Cancer Res Treat. 2017 Dec;166(3):775-785. doi: 10.1007/s10549-017-4444-9. Epub 2017 Aug 18. Breast Cancer Res Treat. 2017. PMID: 28822007 Clinical Trial.
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Gluz O, Liedtke C, Huober J, Peyro-Saint-Paul H, Kates RE, Kreipe HH, Hartmann A, Pelz E, Erber R, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Thomssen C, Jänicke F, Kiechle M, Wallwiener D, Kuhn W, Nitz U, Harbeck N. Gluz O, et al. Among authors: hoffmann g. Ann Oncol. 2016 Jun;27(6):1035-1040. doi: 10.1093/annonc/mdw070. Epub 2016 Feb 18. Ann Oncol. 2016. PMID: 27022068 Free article. Clinical Trial.
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Nitz U, et al. Among authors: hoffmann g. Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Ann Oncol. 2014. PMID: 24827128 Free article. Clinical Trial.
Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.
Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W. Nitz U, et al. Among authors: hoffmann g. Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. Ann Oncol. 2017. PMID: 27634692 Free article. No abstract available.
Abstracts der 3. Gemeinsamen Brachytherapiekonferenz SASRO/DEGRO/OEGRO.
Ott OJ, Strnad V, Pötter R, Hammer J, Hildebrandt G, Resch A, Kovács G, Beckmann MW, Sauer R, Niehoff P, Polgar C, Ostertag H, Major T, Eidtmann H, Jonat W, Kimmig B, Roddiger SJ, Kolotas C, Kuner RP, Martin T, Kurek R, Baltas D, Rogge B, Kautschur H, Hoffmann G, Pollow B, Kontova M, Zamboglou N, Ott O, Lotter M, Gallino A, Mahler F, Niewald M, Jafari F, Hennen B, Wisser L, Fleckenstein J, Rübe Ch, Böhm M, Micke O, Wagner W, Schäfer U, Willich N, Greiner RH, Pallas A, Pajic B, Collen T, Meurer N, Töpfer M, Ries G, Leutloff U, Frei S, Warszawski A, Baumann R, Möller T, Niedermeyer J, Karstens JH, Gripp S, Muskalla K, Pulte T, Ohmann C, Röddiger S, Dannenberg T, Tunn UW, Dimopoulos J, Schard G, Kirisits C, Lang S, Goldner G, Wachter S, Wachter-Gerstner N, Helbich T, Weise C, Bendel M, Kocher M, Müller RP, Engelmann U, Aebersold DM, Isaak B, Vetterli D, Kemmerling L, Thalmann G, Behrensmeier F, Mini R, Baier K, Wulf J, Nürnberg N, Egberts J, Galalae R, Maurer U, Maurer G, Lang K, Zumbé J, Block T, Czempiel H, Machtens S, Ponholzer A, Riedl A, Oismüller R, Somay C, Hawliczek R, Maier U, Madersbacher S, Hoinkis C, Winkler C, Lehmann D, Hakenberg O, Herrmann T, Messer PM, Gottfri… See abstract for full author list ➔ Ott OJ, et al. Among authors: hoffmann g, hoffmann tc. Strahlenther Onkol. 2004 Jun;180 Suppl 1:109-28. doi: 10.1007/BF03356736. Strahlenther Onkol. 2004. PMID: 27137924 German. No abstract available.
Digital-Tier Strategy Improves Newborn Screening for Glutaric Aciduria Type 1.
Zaunseder E, Teinert J, Boy N, Garbade SF, Haupt S, Feyh P, Hoffmann GF, Kölker S, Mütze U, Heuveline V. Zaunseder E, et al. Among authors: hoffmann gf. Int J Neonatal Screen. 2024 Dec 21;10(4):83. doi: 10.3390/ijns10040083. Int J Neonatal Screen. 2024. PMID: 39728403 Free PMC article.
1,827 results